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Progress in understanding the biology of multiple myeloma (MM),
a plasma cell malignancy, has been slow. The discovery of microR-
NAs (miRNAs), a class of small noncoding RNAs targeting multiple
mRNAs, has revealed a new level of gene expression regulation. To
determine whether miRNAs play a role in the malignant transfor-
mation of plasma cells (PCs), we have used both miRNA microarrays
and quantitative real time PCR to profile miRNA expression in
MM-derived cell lines (n 49) and CD138 bone marrow PCs from
subjects with MM (n  16), monoclonal gammopathy of undeter-
mined significance (MGUS) (n  6), and normal donors (n  6). We
identified overexpression of miR-21, miR-106b25 cluster, miR-
181a and b in MM and MGUS samples with respect to healthy PCs.
Selective up-regulation of miR-32 and miR-1792 cluster was
identified in MM subjects and cell lines but not in MGUS subjects
or healthy PCs. Furthermore, two miRNAs, miR-19a and 19b, that
are part of the miR-1792 cluster, were shown to down regulate
expression of SOCS-1, a gene frequently silenced in MM that plays
a critical role as inhibitor of IL-6 growth signaling. We also iden-
tified p300-CBP-associated factor , a gene involved in p53 regula-
tion, as a bona fide target of themiR106b25 cluster,miR-181a and
b, and miR-32. Xenograft studies using human MM cell lines
treated with miR-19a and b, and miR-181a and b antagonists
resulted in significant suppression of tumor growth in nude mice.
In summary, we have described a MM miRNA signature, which
includes miRNAs that modulate the expression of proteins critical
to myeloma pathogenesis.
PCAF  SOCS-1  tumor suppressor gene  MGUS  plasma cells
Multiple myeloma (MM) is a B-cell neoplasm characterizedby the accumulation of clonal malignant plasma cells in the
bone marrow (1). This cancer can occur de novo or develop from
a benign condition called monoclonal gammopathy of undeter-
mined significance (MGUS) at a rate of 1% per year (2–3).
MM cells are endowed with a multiplicity of antiapoptotic
signaling mechanisms, which account for resistance to current
chemotherapy regimens (4). Therapeutic modalities that are
effective inMMmodulate levels of the proapoptotic and antiapo-
ptotic Bcl-2 family of proteins and of inhibitors of apoptosis,
which are primarily regulated by p53 (mutated at low frequency
in MM) (4). It is well known that the bone marrow microenvi-
roment plays a prominent role in the biology of MM; adhesion
of MM cells to the bone marrow stroma triggers cytokine
production, enhances cell proliferation and resistance to che-
motherapy by activation of NFB, phosphatidyl-inositol 3-kinase
PIK/AKT and signal transducer and activator of transcription 3
(STAT-3) pathways through the best characterized MM growth
factor, IL-6 (3, 4).
Detailed genomic analysis has revealed that MM has complex
cytogenetic abnormalities (4–6). For example, aneuploidy, as-
sessed by interphase fluorescence in situ hybridization and DNA
flow cytometry (6), is observed in 90% of cases (5–6). In
addition to chromosome number aberrations, specific cytoge-
netic abnormalities in MM are typically complex, including
reciprocal chromosomal translocations involving the Ig H locus
[eg, t (4, 14), t (6, 14), t (14, 16)], chromosome 13 monosomy, loss
of the short arm of chromosome 17, and gains or amplifications
of the long arm of the chromosome 1 (3). The presence of RAS
family member mutations at codons 12, 13, and 61 of NRAS and
KRAS, has been described in 30 to 35% of MM patients and
45% of MM cell lines (7), and more importantly it seems that is
the major genetic difference between MM and MGUS (3–7).
Despite recent advances in oncogenomics andMMcell-stroma
interactions, further studies are needed to identify critical play-
ers in MM pathogenesis that could be targeted by pharmaco-
logical intervention to improve outcomes for this still incurable
disease. The advent of new techniques, such as microarray gene
expression, including noncoding RNAs, may lead to an improved
understanding of MM biology by establishing associations be-
tween gene expression changes and MM molecular and clinical
features, as shown by us for chronic lymphoid and acute my-
elogenous leukemia (8–9).
MicroRNAs (miRNAs) are noncoding RNAs of 19 to 25
nucleotides in length that regulate gene expression by inducing
translational inhibition and degradation of their target mRNAs
through base pairing to partially or fully complementary sites
(10). MiRNAs are involved in critical biological processes,
including development, cell differentiation, stress response, apo-
ptosis, and proliferation (10). Recently, specific miRNA expres-
sion patterns have been linked to hematopoiesis and cancer
(11–13). Little is known, however, about miRNA expression in
MM. A recent study has shown that, in IL-6 dependent MM cell
lines, miR-21 transcription is controlled by IL-6 through a
STAT-3 mechanism. Moreover, ectopic miR-21 expression is
sufficient to sustain growth of IL-6-dependent cell lines in the
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absence of IL-6 (14). Here, we have used both miRNA microar-
rays and quantitative RT-PCR to assess the miRNA expression
in MM-derived cell lines and CD138 bone marrow plasma cells
(PCs) from MM subjects, MGUS, and normal donors. Our
findings define an miRNA signature related to expression and
regulation of proteins associated with malignant transformation
of PCs.
Results
A Characteristic miRNA Signature Differentiates MGUS from Healthy
PCs. Current models assume that MM evolves through a multi-
step transformation process (Fig. 1A) (15). To identify specific
alterations associated with early pathogenetic events of MM, we
profiled five CD138 PCs fromMGUS subjects and four healthy
PCs [see supporting information (SI) Table S1 for patient
characteristics] by using our miRNA microarray platform. We
first compared MGUS to the healthy counterpart PCs by using
the univariate t test within BRB tools (class comparison) (Fig. 1B
and Table S2). We found 48 miRNAs significantly deregulated
(P 0.05); 41 miRNAs were up-regulated and 7 down-regulated
in MGUS with respect to normal CD138 PCs (see Table S2, a
representative list is shown in Fig. 1B). The most up-regulated
miRNAs in MGUS were miR-21, which was described by other
groups to be up-regulated in MM as well (14), miR-181a, known
to have a role in B and T cell differentiation (16), and the
oncogenic clustermiR-106b25, in particularmiR-93,miR-106b,
and miR-25 (see Fig. 1B and Table S2).
MiRNA Signatures in MM Patients and Cell Lines. To determine
whether miRNAs are deregulated inMM, we analyzed the global
miRNA expression in 41 MM-derived cell lines (Table S3),
CD138 untreated bone marrow PCs from 10 MM, and 4
normal CD138 PCs using our miRNA microarray (17). The
degree of CD138PCs purity after AutoMACs automated
separation system (Miltenyi-Biotec) and the clinical features of
the MM cases and normal PCs are listed in Table S1. First, we
compared miRNA expression in primary tumors and cell lines
compared to CD138 healthy controls using univariate t test
within by BRB (Table S4). Our analysis revealed up-regulation
of 60 and down-regulation of 36 miRNAs in MM subjects and
cell lines compared to CD138 healthy controls (see Fig. 1C and
Table S4). All miRNAs have a fold-change 2 and a P value 
0.01. Because miRNA expression in cell lines could be also
deregulated because of prolonged in vitro culture, we analyzed
the miRNA expression only in MM subjects versus healthy PCs
(Table S5). We found 37 up- and 37 down-regulated miRNAs in
MM subjects with respect to normal PCs with a fold-change 2
and a P value  0.01 (see Table S5). Approximately 90% of the
up-regulated miRNAs (34 out of 37) and 30% of the down-
regulated miRNAs (10 out of 37) were in common to the
combined group ofMM subjects and cell lines, thereby validating
our approach of combining cell lines and MM subject samples,
at least for the analysis of up-regulated miRNAs (see Fig. 1C and
Table S6). A Venn diagram in Fig. S1 shows the common
miRNAs between these two groups of comparison. Similar to the
signature observed in MGUS, miR-21 and the miR-106a92
cluster were found up-regulated in MM subjects and cell lines
(see Fig. 1C and Table S3). However, we identified that miR-32
and the cluster miR-1792 (in particular miR-19a and b) were
significantly up-regulated only in MM samples but not in MGUS
or healthy PCs (see Fig. 1C), indicating a possible role in the
malignant transformation from MGUS to MM.
Validation of the miRNA Signatures by q-RT-PCR. To validate the
microarray results we performed quantitative real time PCR
(q-RT-PCR) formiR-32,miR-17–5,miR-19a,miR-19b,miR-20a,
miR-92, miR-106a (miR-1792 cluster), miR-106b, miR-93 and
miR-25 (miR-106b25 cluster), miR-328, and miR-181a and b
using an independent set of randomly chosen CD138PCs from
healthy subjects (n  3), MM patient samples (n  6), and
MGUS (n  3) (see Table S1), all from different donors, plus a
set of MM cell lines (n  15) (see Table S1). We confirmed the
over-expression of the miR-106b25 cluster in MGUS and MM
samples with respect to the CD138 healthy PCs (Fig. S2A).
Although the miR-106b25 cluster shares a high degree of
homology with the miR-1792 cluster (Fig. 1D), and an onco-
genic role was reported for both (18–20), we are confident of the
specificity of stem-loop q-RT-PCR for the analysis of highly
similar miRNAs; a previous report from our laboratory showed
exquisite specificity of miR-106b, miR-93, and miR-25 primers
(20). Mature miR-181a was over-expressed in 2 out of 3 MGUS,
6 out of 6 MMs, and 9 out of 15 cell lines with an average on the
differential expression shown in Fig. S2B. In addition, miR-181b
was also over-expressed in MM and MGUS, albeit at a lower
degree than miR-181a (see Fig. S2B). We further validated the
over-expression of the miR-32 and miR-1792 cluster (Fig. S2
C–F) in MM patients and cell lines. Consistent with the array
data, the two miR-1792 cluster members, miR-19a and b and
miR-32, were highly over-expressed in 6 out of 6MMPC samples
and 15 out of 15 cell lines (see Fig. S2 C and F). Principally, we
found that miR-19a and b have a fold-change 100 times (see
Fig. S2F), although they show very low expression in 1 out of 3
Fig. 1. MM and MGUS express a distinct spectrum of miRNA in comparison
to normal CD138 PCs. (A) Schematic drawing showing the multistep molec-
ular process of PC transformation. (B) Representative list of the miRNAs
significantly deregulated in MGUS versus normal PCs analyzed in this study.
The asterisks indicate the specific associated cluster. (C) Representative list of
the common deregulated miRNAs in the comparison classes MM patient
versus normal PCs and PCs MM versus normal PCs analyzed in this study. The
asterisks indicate the specific associated cluster. (D)miR-17microRNA clusters.
Three paralog families of miRNA precursors can be identified: miR-17/18/18X/
20/93/106a/106b/93 (yellow),mir-19a/19b-1/19b-2 (blue) andmir-92-1/92-2/25
(green).
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MGUS and almost no expression in 2 out of 3 MGUS and 3 out
of 3 healthy PC samples, validating our initial array results and
suggesting that these miRNAs are MM-specific.
Several miRNAs Up-Regulated in MM Target p300-CBP-Associated
Factor , a Positive Regulator of p53. One of the most up-regulated
miRNAs in MGUS and MM patients and cell lines were
miR-181a and b, and miR-106b25, while miR-32 was prefer-
entially up-regulated in MM. Using ‘‘in silico’’ target prediction
software [Target Scan (21), Pictar (22)], we found that those
miRNAs are predicted to target the 3-UTR of the p300-CBP-
associated factor (PCAF) (Fig. 2A). PCAF is a histone acetyl-
transferase involved in the reversible acetylation of various
transcriptional regulators, including the tumor suppressor pro-
tein p53 (23). Recently, Linares and colleagues have shown that
PCAF possesses an intrinsic ubiquitination activity that is critical
for controlling Hdm2 expression levels, and thus p53 (24) that is
rarely mutated (5–10% of cases) or deleted at diagnosis in MM
(25–26). To examine whether these miRNAs could regulate
PCAF, first we analyzed PCAF expression by q-RT-PCR (Fig.
S3A) and Western blotting (Fig. S3B) in 15 MM cell lines. As
control, we used two CD138PCs isolated from healthy donors.
We found that PCAF expression is almost absent (10-fold less
than in control) in 10 out of 15 cell lines, whereas the remaining
5 cell lines displayed very low expression. To investigate whether
this gene was deleted at the genomic level we performed whole
genome comparative genomic hybridization analysis of all 15
MM cell lines using the Affymetrix SNP 6.0 arrays. However, we
did not observe deletion of the PCAF gene (data not shown).
Second, we cloned the PCAF 3 UTR into a luciferase reporter
vector and cotransfected with the candidate miRNAs mimics or
scrambled oligonucleotides and performed luciferase assays as
described in Methods. We found that miR-181a and b (Fig. 2B),
106b25 cluster and 32 (Fig. 2 D and B), interact with the PCAF
3UTR in vitro. However, this interaction was less significant
with miR-92 (Fig. 2C) and no interaction was observed with
miR-19a and b (data not shown). Mutation of the predicted
miRNA binding sites in the reporter vector abrogated this effect,
indicating that these miRNAs directly interact with the PCAF
3UTR. To confirm the biological role of thesemiRNAs in PCAF
regulation in MM cells, we validated the in vitro studies by
antagonizing endogenous miR-181a, 181b, 25, 93, 106b and 92
using antisense oligos (ASOs) in U266 and JJN3 MM cell lines.
In both cell lines the antagomiRs induced accumulation of PCAF
protein expression at 72 h after transfection (Fig. 2 E and F). By
contrast over-expression of the same miRNAs by oligonucleo-
tide transfection reduced PCAF expression in the K562 cell line
(Fig. 2 G and H). MiR-19a and b did not influence PCAF
expression (Fig. 2H) and miR-92 had little effect on its expres-
sion (see Fig. 2F), confirming the luciferase expression data (see
Fig. 2C). To determine whether the miRNA regulators of PCAF
are able to indirectly affect p53 expression, we transfected MM1
cells with anti-miR-181a and b or with all antagomiRs simulta-
neously (anti-miRs-181s, 93, 106b, 25, 32) exposed the cells to
UV (UV) radiation (Fig. 2I) andmeasured the expression of p53
and PCAF by q-RT-PCR (see Fig. 2I). Fig. S4A shows the
re-expression of PCAF protein after 48 h of antagomiRs treat-
ment. The antagonizing activity of transfectant oligos is shown
in Fig. S4B. After UV treatment, p53 mRNA expression was
almost doubled in cells transfected with antisense miR-181a and
b, while it increased sixfold after nucleoporation with all an-
tagomiRs simultaneously (see Fig. 2I). Furthermore, after trans-
fection of antisense miR-181a and b oligos in MM1s, we treated
the cells with a small-molecule MDM2 antagonist nutlin-3a (10
M) and measured p53 by Western blotting. We found that the
cells transfected with miR-181 ASOs displayed a higher level of
p53 protein compared to scrambled and miR-92 ASOs at 9 and
12 h (Fig. 2L). Together, these data show that the miR-106b-25
Fig. 2. miR-181s, 106b-25 cluster, 32 target PCAF. (A) miRNAs predicted to
interact withPCAFgene in several consensus binding sites at its 3-UTR, according
to ‘‘in silico’’ target Target Scan prediction software. (B–D) Luciferase assay
showing decreased luciferase activity in cells cotransfected with pGL3-PCAF-
3UTR and miR-181s (B), miR-32/miR-25/miR-92 (C), and miR-93/miR-106b (D)
oligonucleotides. Deletion of six bases in three putativemiR-181s,miR-106b/miR-
93, and miR-32/miR-25/miR-92 binding sites, complementary to miRNAs seed
regions, abrogates this effect (MUT). Bars indicate firefly luciferase activity nor-
malized to Renilla luciferase activity SD. Each reporter plasmid was transfected
at least twice (on different days) and each sample was assayed in triplicate. (E, F)
Immunoblot analyses showing PCAF and GADPH expression after transfection
withmiR-181s andmiR-106b/25 clusterASOs in U266 cells (E) and withmiR-181s,
miR-32andmiR-92ASOs inJJN3cells (F),ormimics inK562cells (G,H). (I)Real-time
RT-PCR analyses for p53 and PCAF expression in MM1s cells transfected with
miR-181aandbor withmiR-181aandbandmiR-106b/25 together ASOs (pool) or
with scrambled oligonucleotide at 48 h after transfection and after 4 h of UV
treatment. The PCR products for both genes were normalized to GADPH and
ACTIN expression. The bar-graph represents the mean values observed in four
separate studiesSE. (L) Immununoblotanalysis showingp53proteinexpression
after 48 h of miR-181a, miR-181b, miR-92 and scrambled ASOs transfection in
MM1 cells after 9 h and overnight incubation with 10 M nutlin-3a; GADPH was
internal loading control. Densitometry based on GADPH levels shows increased
level of p53 in presence of miR-181a and miR-181b ASOs in MM1s cells.
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cluster, miR-32, miR-181a and b target PCAF and through this
gene, indirectly control p53 activity in myeloma.
miR-19a and miR-19b Target SOCS-1, a Negative Regulator of IL-6R/
STAT-3 Pathway. Our findings indicate that miR-19a and b are
up-regulated 100-fold in patient samples, 2,000 times in the
cell lines (Fig. S2F), and are both almost absent in normal PCs
and MGUS. These data suggest that both miRNAs contribute to
the development of MM. Therefore, we searched for miR-19a
and b mRNA targets, which are involved in myeloma pathogen-
esis, using available target-prediction software [Target Scan (21),
Pictar (22)]. Among 100 predicted targets, SOCS-1 has been
implicated in the negative regulation of several cytokine path-
ways including IL-6, particularly the Jak/STAT pathways (27),
and is frequently silenced by methylation in MM (28). We
therefore hypothesized that the high levels of miR-19s levels in
MM samples may play an important role in the constitutive
activation of Jak/STAT-3 signaling through down-regulation of
its negative regulator SOCS-1. To examine our hypothesis, we
first assessed its expression in 15 MM cell lines and two healthy
CD138 PCs and found almost no protein expression in 13 out
of 15 cell lines compared to control (Fig. 3A). To examine
whether SOCS-1 reduced expression levels could be a conse-
quences of up-regulated miR-19a and b in MM cells, we per-
formed Western blot analysis using SOCS-1 antibody after
transfection of candidate antagomiRNAs or scrambled oligonu-
cleotides in U266 (which has an active IL-6 autocrine loop) (29)
and JJN3 MM cell lines that display reduced SOCS-1 expression
(Fig. 3D). Moreover,miR-19a andmiR-19bmimics inhibited the
expression of a reporter vector containing SOCS-1 3UTR, while
mutation of the predicted miRNA-binding site abrogated this
effect (Fig. 3 B and C). As shown in Fig. 3 C and D, there was
significant up-regulation of SOCS-1 protein in U266 and JJN3
cells transfected with antisense oligonucleotide for miR-19a and
b but not with scrambled oligonucleotides. Furthermore, con-
stitutive STAT-3 phosphorylation in U266 cells was markedly
decreased at 72 h after transfection by anti-miR-19s but not by
scrambled (Fig. 3E). The ASOs activity at 72 h was detected by
q-RT-PCR (Fig. 3F). These studies suggest a role of miR-19s in
the IL-6 antiapoptotic signal in the pathogenesis and malignant
growth of MM.
miR-1792 Cluster Target BIM in MM Cells. Because themiR-1792
cluster has been shown to target the proapoptotic gene, BIM
(19–20), we examined whether BIM expression is modulated by
miR-1792 in MM cells. U266 cells were transfected with
miR-19s ASOs and BIM expression was evaluated using immu-
noblot. We found a significant increase of BIM protein levels at
48 h after treatment with anti-miR-19s compared to scrambled
oligonucleotides (Fig. S5). Together, these results have sup-
ported previous published data (19–20) that show BIM as a
direct target of miR-1792 and suggest a possible mechanism
through which over-expression of miR-1792 contributes to the
antiapoptotic signals in MM.
Ectopic Repression of miR-19s and miR-181a and b in MM Cell Lines
Leads to Significant Suppression of Tumor Growth in Nude Mice. To
explore the in vivo relevance of our observations, we examined
the tumorigenicity of U266 and JJN3 cells in athymic nu/numice
after silencing of the endogenous miR-19s and miR-181a and b.
Two independent experiments, each using 16 mice for each cell
line, were conducted. U266 or JJN3 cells were transfected with
ASOs or scrambled oligonucleotides in vitro. We confirmed
transfection efficiency (80% for U266 and JJN3) using
BLOCK-IT Fluorescent Oligo (Invitrogen). Twenty-four hours
later 3  107 viable cells for each group, re-suspended in 100 l
of BD matrigel matrix, were injected s.c. into the right flank of
nude mice. The relative expression levels of the endogenous
miR-19s andmiR-181a and b after ASO transfection was assessed
by q-RT-PCR to confirm the down-regulation of these miRNAs
in both MM cell lines (data not shown). We found that after 2
weeks of cell inoculation, 70% of mice injected with MM cells
transfected with scrambled oligonucleotide developed measur-
able tumors. By contrast, mice transplanted with cells expressing
antagomiRs showed significant inhibition of tumor growth com-
pared with controls (P 	 0.01) (Fig. 4 A and B). Both cell lines
treated with anti-miR-19s showed tumor volumes 10-fold
reduced and tumors treated with antago miR-181s were three
times smaller in JJN3 cells and 10 times smaller in U266 cells,
Fig. 3. miR-19s target SOCS-1 in MM cell lines. (A) Immunoblot analysis with
antisera against SOCS-1 and GADPH in 15 MM cell lines and two CD138PCs
from healthy donors (control). (B) Predicted highly conserved consensus bind-
ing site in human, mouse, rat, and dog formiR-19s on the 3UTR of SOCS-1. (C)
Relative luciferase activity in MEG01 cells transiently cotransfected with lucif-
erase reporter vector containing the 3 UTR of SOCS-1 and miR-19s or scram-
bled oligonucleotides. Deletion of the six bases in the putative miR-19s
binding site, complementary to miRNA seed region, abrogates this effect
(MUT). Bars indicate firefly luciferase activity normalized to Renilla luciferase
activity SD. Each reporter plasmid was transfected at least twice (on differ-
ent days) and each sample was assayed in triplicate. (D) Western blot showing
SOCS-1 protein in whole cell lysates from U266 and JJN3 cells at 48 h after
transfection with scrambled oligonucleotides or miR-19a, miR-19b, or both
ASOs. GADPH was used as loading control. Densitometry based on GADPH
levels shows increased level of SOCS-1 in presence of miR-19a or miR-19b or
together ASOs in U266 and JJN3 cells. (E) Western blot showing that miR-19s
modulate expression of activated STAT-3 in U266 cells in vitro. Cells were
transfected with anti-miR-19s or negative control (Scr) miRNA inhibitors in
vitro, and cell lysates were obtained after 72 h. Densitometry based on STAT-3
levels shows decreased level of P-STAT-3 in presence ofmiR-19s. (F) Stem-loop
q-RT-PCR to validate the expression of endogenous miR-19a and miR-19b, at
72 h after transfection of U266 cells with antagonizing oligonucleotides, after
normalization with RNU6B.
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P 0.02 and P 0.01, respectively. Importantly, complete tumor
suppression was observed in two mice injected with U266 cells
treated with anti-miR-19s. The average tumor volume after 4
weeks for U266 cells was 308.5 mm3 and for JJN3 cells was 225
mm3. Only 50% of mice injected with MM cells transfected with
the antagomiR-19s andmiR-181s developed measurable tumors
at 4 weeks. The average tumor volume for U266/anti-miR-19s
was 19.5 mm3 and for U266/anti-miR-181s was 14 mm3. Similar
results were observed with JJN3 MM cells, with average tumor
volumes of 25 mm3 and 80 mm3 for anti-miR-19s and anti-miR-
181s, respectively (see Fig. 4 A and B). Taken together, these
results strongly suggested an oncogenic role of these miRNAs in
MM and we speculate that the stronger effect of anti-miR-19s is
related to the IL-6 dependence of U266.
Discussion
Over the past few years several studies have illustrated the
biological relevance of miRNAs for the differentiation of normal
hematopoietic cells and the contribution of deregulated miRNA
expression in malignant counterparts (11, 30, 31). Our study has
provided a unique comprehensive global miRNA expression
profiling of MM, MGUS and contrasted these expression pat-
terns with that of normal PCs. The similar miRNA expression
pattern observed in MM cell lines and in primary newly diag-
nosed MMs supports the research design of this study. In
addition, previous MM microarray studies have combined MM
cell lines with primary patient samples, validating our strategy
(32). We sought to identify a miRNA signature that could be
associated with a MM multistep transformation process from
normal PCs via MGUS to clinically overt myeloma, conscious of
limitations because of the low number of MGUS and primary
tumor samples. In MGUS patients, we identified up-regulated
miRNAs with oncogenic function, such as the miR-21 and the
miR-106b25 cluster. MiR-21 is up-regulated in many solid and
hematological tumors (11, 25). The ectopic expression ofmiR-21
in glioblastoma cells blocks apoptosis (33), while silencing its
expression in several cancer cells inhibits cell growth and leads
to increased apoptotic cell death by unblocking the expression of
its targets: tumor suppressor genes like phosphatase and tensin
homolog (PTEN) and protein programmed cell death 4
(PDCD4) (34). Petrocca and colleagues (20), have shown that
the miR-106b25 cluster plays a role in gastric cancer tumori-
genesis by targeting the proapoptotic BIM and p21. Thus, these
two miRNAs may contribute to earlier steps in plasma cell
transformation by blocking apoptosis, promoting PC survival,
and predisposing to secondary genetic abnormalities that will
ultimately result in a full blown malignancy.
In MM (including MM cell lines and primary tumors versus
normal PCs) we identified a signature comprised of multiple
up-regulated miRNAs, including among others miR-32, miR-21,
miR-1792, miR-10625, and miR-181a and b. While miR-
10625, miR-181a and b, and miR-21 were up-regulated also in
MGUS patients with respect to normal PCs, miR-32 and the
miR-1792 cluster were highly expressed only in MM patients,
suggesting that these miRNAs are MM-specific. Besides RAS
mutations, no other genetic abnormality has been found to
differentiate MGUS from MM (3). Therefore, miR-32 and the
miR-1792 cluster may represent MM-specific genetic changes.
However, this will require further independent validation be-
cause we used a small number of patient samples and normal
plasma cells.
Similar to the miR-10625 cluster, the oncogenic role of the
miR-1792 cluster in B cell lymphoma is well known and several
known proapoptotic genes, including PTEN, E2F1, and Bcl2l11/
BIM are confirmed as targets of miR-1792 (35–36). Recently,
Ventura and colleagues (19) have shown that the miR-1792
cluster is also essential for B cell development and that the
absence of miR-1792 leads to increased levels of the proapo-
ptotic protein BIM and inhibits B cell development at the pro-B
to pre-B transition. However, given the nearly identical se-
quences, it is very likely that miR-106b25 and miR-1792
clusters cooperate in exerting similar, if not identical, functions
as in targeting BIM (19–20).
Our study provided important functional insights about miR-
NAs deregulated in MM. We have confirmed that the proapo-
ptotic BIM is a target of the miR-1792 cluster in MM cells.
Therefore,miR-1792, along withmiR-21, blocks apoptosis and
promotes cell survival. On the other hand, miR-106b25, miR-
181a, andmiR-32 but notmiR1792 cluster (specificallymiR-19s
and miR-92), target PCAF, a p53 positive regulator. We spec-
ulate, consistent with the low frequency of p53mutations inMM,
that down-regulation of PCAF by the miR-106b25 cluster,
miR-181s, and miR-32, keeps p53 at low level or partially
inactivated by controlling its stability through Hdm2 (24) and
working as a histone acetyltransferase (23). We have also
described the specific role of miR-19s on the STAT-3/IL-6R
negative regulator SOCS-1. In fact, IL-6 pathways in MM are
among the best characterized survival pathways participating in
PC transformation and oncogenesis through STAT-3, impacting
apoptosis regulators such as the Bcl-2 family members (1, 16).
Our findings demonstrate that the up-regulation of miR-19s in
MM could contribute to SOCS-1 down-regulation and IL-6
activation at later stages in MM pathogenesis.
The role of miR-19s and miR-181s in MM cells as oncomiR-
NAs was confirmed by in vivo studies. Our data demonstrate
Fig. 4. Antagonizing miR-19s and miR-181s expression in MM cell lines
resulted in significant tumor suppression in nude mice. U266 and JJN3 cells
(30 106 cells) were injected subcutaneously into the flanks of nude mice with
100 l of matrigel solution 24 h after transfection with miR-19s and miR-181s
ASOs or scrambled oligonucleotide. Mice were killed on day 35 and tumor
volumes were calculated. (A) Time course of tumor growth of U266 cell line.
(B) Time course of tumor growth of JJN3 cell line; tumors treated withmiR-19s
and miR-181s ASOs were significantly smaller than tumors of scrambled
groups for both cell lines. (Scale bar, 10 mm.)
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significant tumor regression of transplanted tumors after treat-
ment with miR-19s and 181s antagomiRs. These data may
suggest that miRNAs could have a therapeutic potential in
antagonizing the growth of transformed PCs.
In conclusion, we reported distinctive miRNA signatures in
MM and MGUS, characterized by over-expression of miRNAs
with known oncogenic activity. Our data provided insights into
the miRNA function in MM by establishing links with the
regulation of critical pathways in MM by miRNAs, including
apoptosis, survival, and proliferation. These results indicate an
additional level of control by this class of regulatory molecules
in the multistep process associated with malignant transforma-
tion of PCs.
Materials and Methods
RNA Extraction andmiRNAMicroarray Experiments. RNA extraction and miRNA
microchip experiments were performed as described in detail elsewhere
(37). The miRNA microarray is based on a one-channel system (35). Five
micrograms of total RNA was used for hybridization on the Ohio State
University custom miRNA microarray chips (OSUCCC version 3.0), which
contains 1,100 miRNA probes, including 345 human and 249 mouse
miRNA genes, spotted in duplicates.
RT-PCR. The single tube TaqMan miRNA assays were used to detect and
quantify mature miRNAs as previously described (10) using ABI Prism 7900HT
sequence detection systems (Applied Biosystems). Normalization was per-
formed with RNU6B. Comparative real-time PCR was performed in triplicate,
including no-template controls. Relative expression was calculated using the
comparative Ct method.
ASOs and Mimics Transfection Experiments. Cells were transfected by using
nucleoporation (Amaxa) kit V (for JJN3 and MM1s cell lines) and kit C (for U266
cell line) using 100 nM miRNA precursors (Ambion), or 100 nM LNA miRNA
antisense oligonucleotides (Ambion). Protein lysates and total RNA were
collected at the time indicated. miRNA processing and expression were veri-
fied by Northern blot and stem-loop q-RT-PCR. We confirmed transfection
efficiency (80% for U266 and JJN3 and 50% for MM1s) using BLOCK-IT
Fluorescent Oligo (Invitrogen) for all of the cell lines. Untreated cells trans-
fected with negative control oligonucleotides were used as a calibrator.
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